• Macrogenics Inc., of Rockville, Md., set terms for its initial public offering of 4 million shares at $14 to $16 per share. The offering is expected to raise about $60 million to support the company’s pipeline of monoclonal antibody-based therapeutics for cancer and autoimmune disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter